Borealis Biosciences, Inc.

Borealis Biosciences was founded on the premise that a convergence of scientific and translational breakthroughs is enabling the field of RNA medicines to treat kidney diseases and beyond. The company is backed by founding investor Versant Ventures and Novartis AG, and has a strategic collaboration with the pharma.

https://borealisbio.com/

11-50 employees

Growth Trajectory

Borealis Biosciences shows potential for growth by expanding its RNA therapy programs for kidney diseases with a focus on unmet needs and improving patient outcomes. Their strategic research collaboration with Novartis and substantial Series A funding support further research and development. The company is positioned to address validated targets out of reach for traditional modalities, potentially leading to new market opportunities.

Technical Challenges

Directing RNA to kidney cells with precision.

Addressing validated causal targets not amenable to traditional small molecule or biologic modalities.

Integrating translational systems biology and data sciences to advance RNA medicine development.

Tech Stack

RNA therapeuticsTargeted delivery of RNA therapeuticsTranslational systems biologyData sciencesTranslational biologyChemistryDMPKPharmacology

Team Size

Key Risks

Challenges in delivering therapeutic payloads to specific kidney cell types.

Competition from traditional small molecule and biologic modalities for kidney disease treatments.

The necessity of integrating data sciences and translational biology for effective RNA medicine development.

Potential regulatory hurdles in advancing RNA therapies for kidney disease.

Opportunities

Leveraging advancements in RNA therapeutics and targeted delivery to kidney cells.

Expanding beyond kidney diseases to address other unmet medical needs.

Capitalizing on the increasing demand for precision medicine approaches in renal disease.

Strengthening partnerships with pharmaceutical companies like Novartis for program development and potential acquisition.

Live Data Stream

Access Our Live VC Funding Database

30,000+ funded startups

tracked in the last 3 months

B2B verified emails

of key decision makers

Growth metrics

Real-time company performance data

Live updates

of new VC funding rounds

Advanced filters

for sophisticated queries

API access

with multiple export formats

Access Database

Updated every 5 minutes